|
|
Bailey McCann, Opalesque New York: Boston-based Omega Funds today announced the closing of its eighth fund with $647 million in capital commitments.
Omega Fund VIII, was oversubscribed and beat its $600 million target, reaching the hard cap. With Fund VIII, the firm will continue to execute its strategy of creating and investing in life sciences companies in the U.S. and Europe that target severe, unmet medical needs.
"We believe our broad investment strategy is well-positioned for navigating this period of macro and policy uncertainty. We look forward to contributing our capital, expertise, and network connectivity in partnering with entrepreneurs, founders, co-investors, and the broader community to transform the standards of care for severe diseases," said Francesco Draetta, Managing Director of Omega Funds.
The firm's investments have resulted in 50 exits via M&A, and 47 public listings. Omega's recent M&A exits and IPOs include SoniVie (acquired by Boston Scientific), Scorpion Therapeutics (acquired by Eli Lilly), Kestra Medical Technologies (NASDAQ: KMTS), Beta Bionics (NASDAQ: BBNX), Upstream Bio (NASDAQ: UPB), Bicara Therapeutics (NASDAQ: BCAX), Morphic Therapeutic (NASDAQ: MORF, acquired by Eli Lilly), EyeBio (acquired by Merck), Imago BioSciences (NASDAQ: IMGO, acquired by Merck), Amunix Pharmaceuticals (acquired by Sanofi), and Chord Therapeutics (acquired by Merck KGaA)....................... To view our full article Click here
|
|